Beyond Air to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020
GARDEN CITY, N.Y., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)
for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that
Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the 32nd Annual Piper Sandler Healthcare Conference being held virtually from December 1-3, 2020.
Beyond Air will provide a pre-recorded investor presentation and will be available for virtual one-on-one meetings during the conference.
|Date and Time:||December 1-3, 2020|
|Location:||Piper Sandler is hosting this year’s event virtually|
|Webcast:||Access to a webcast of Beyond Air’s presentation will be available through Piper Sandler|
About Beyond Air, Inc.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.